Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Descripción general
Resumen del artículo
This retrospective study found that treatment with hydroxychloroquine alone or in combination with azithromycin was associated with reduced mortality in hospitalized COVID-19 patients. Independent predictors of mortality included age, chronic kidney disease, and disease severity upon admission.
Explícamelo como si tuviera cinco años
In a large hospital study, COVID-19 patients treated with hydroxychloroquine, with or without azithromycin, seemed to have a better chance of survival. More research is needed to confirm this.
Posibles conflictos de intereses
One author disclosed receiving speaker's bureau honoraria from Bayer. Another author disclosed receiving similar honoraria from Gilead, ViiV, and Janssen. One author received consultation honoraria from ContraFect. All other authors declared no conflicts of interest.
Limitaciones identificadas
Explicación de la calificación
Despite the large sample size, the retrospective and non-randomized design significantly limits the strength of the findings. The study's findings should be interpreted cautiously and validated by prospective randomized controlled trials before drawing firm conclusions.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →